|
SERPINE1
|
0.400 |
Biomarker
|
disease |
BEFREE |
Negative correlations between antioxidative defense parameters and BMI, abdominal obesity, insulin secretion, systolic blood pressure and atherogenic lipid factors, as well as correlations between PAI-1 and insulin resistance and basal glycemia in the metabolic syndrome group contribute to accelerated atherosclerosis.
|
17848118 |
2007 |
|
SERPINE1
|
0.400 |
Biomarker
|
disease |
BEFREE |
One of the well-known physiological substances that induce the PAI-1 gene is tumor necrosis factor-alpha, which also induces other possible risk factors of atherosclerosis, intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1.
|
9187938 |
1997 |
|
SERPINE1
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Plasma PAI-1 levels and 4G/4G genotype frequency were significantly higher in the severe atheromatosis group compared to the other groups (p<0.001).
|
22011808 |
2011 |
|
SERPINE1
|
0.400 |
Biomarker
|
disease |
BEFREE |
Plasminogen activator inhibitor ( PAI -1) is associated with excessive fibrin accumulation, thrombus formation, and atherosclerosis.
|
30371230 |
2018 |
|
SERPINE1
|
0.400 |
Biomarker
|
disease |
BEFREE |
Plasminogen activator inhibitor type 1 (PAI-1) is a major physiologic regulator of the fibrinolytic system and has recently gained recognition as a modulator of inflammation and atherosclerosis.
|
16968709 |
2006 |
|
SERPINE1
|
0.400 |
Biomarker
|
disease |
BEFREE |
Plasminogen activator inhibitor type-1 (PAI-1) has already been associated with atherosclerosis; myocardial infarction; and cardiovascular disease risk factors such as obesity, insulin resistance, and dyslipidemia.
|
20127289 |
2010 |
|
SERPINE1
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Promoter (4G/5G) plasminogen activator inhibitor-1 genotype and plasminogen activator inhibitor-1 levels in blacks, Hispanics, and non-Hispanic whites: the Insulin Resistance Atherosclerosis Study.
|
12719278 |
2003 |
|
SERPINE1
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Since NF-kappaB-mediated gene products, such as fibrinogen and PAI-1, are known to facilitate hypercoagulation, thrombosis and vascular events, we suggest that nilvadipine has a direct beneficial effect separate from its anti-hypertensive properties by inhibiting NF-kappaB-dependent gene expression and eventually inhibiting atherosclerosis.
|
15530472 |
2004 |
|
SERPINE1
|
0.400 |
Biomarker
|
disease |
BEFREE |
Studies in mice with targeted gene inactivation of t-PA, u-PA, PAI-1, the urokinase receptor (u-PAR), and plasminogen (Plg) revealed (1) that deficiency of t-PA or u-PA increase the susceptibility to thrombosis associated with inflammation and that combined deficiency of t-PA:u-PA or deficiency of Plg induces severe spontaneous thrombosis; (2) that vascular injury-induced neointima formation is reduced in mice lacking u-PA-mediated plasmin proteolysis, unaltered in t-PA- or u-PAR-deficient mice and accelerated in PAI-1-deficient mice, but that it can be reverted by adenoviral PAI-1 gene transfer; and (3) that atherosclerosis in mice doubly deficient in apolipoprotein E (apoE) and PAI-1 is reduced after 10 weeks of cholesterol-rich diet.
|
9186598 |
1997 |
|
SERPINE1
|
0.400 |
Biomarker
|
disease |
LHGDN |
Studies with transgenic mice have revealed a functional role for PAI-1 in wound healing, atherosclerosis, metabolic disturbances such as obesity and insulin resistance, tumor angiogenesis, chronic stress, bone remodeling, asthma, rheumatoid arthritis, fibrosis, glomerulonephritis and sepsis.
|
15634264 |
2005 |
|
SERPINE1
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The aim of this cross-sectional study was to evaluate the differences in plasma levels of plasminogen activator inhibitor-1 (PAI-1) and of von Willebrand factor (vWF) as endothelial hemostatic markers and carotid intima-media thickness (C-IMT) as a morphologic marker for atherosclerotic vascular disease among dyslipidemic individuals with apoB levels higher, estimated or lower based on regression equation of apoB vs non-HDL-C.
|
28502501 |
2018 |
|
SERPINE1
|
0.400 |
Biomarker
|
disease |
BEFREE |
The effect of PAI-1 upon angiogenesis is also involved in atherosclerosis, in which high levels of PAI-1 expression are observed.
|
17509745 |
2007 |
|
SERPINE1
|
0.400 |
Biomarker
|
disease |
BEFREE |
The levels of CLOCK, leukemia inhibitory factor (LIF), intercellular adhesion molecule 1 (ICAM-1), perilipin 2 (ADFP), nuclear factor kappa B (NF-κB), and plasminogen activator inhibitor-1 (PAI-1), as well as the number of atherosclerotic plaques were elevated in the AS mouse model, as compared with the control group.
|
30124738 |
2018 |
|
SERPINE1
|
0.400 |
Biomarker
|
disease |
BEFREE |
The results indicate that ghrelin inhibits both basal and TNF-alpha-induced PAI-1 production via NF-kappaB pathway in HepG2 cells, and suggest that the peptide plays a therapeutic role in atherosclerosis, especially in obese patients with insulin resistance, in whom ghrelin levels were reduced.
|
18700166 |
2008 |
|
SERPINE1
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Therefore, we performed this study to better assess the relationship between PAI-1 genetic variations and atherosclerosis.
|
29908999 |
2018 |
|
SERPINE1
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
These criteria identify targets for therapy designed to normalize expression of PAI-1 and retard progression of atherosclerosis in subjects with elevated concentrations of FFA in blood including those with insulin resistance.
|
12669679 |
2002 |
|
SERPINE1
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
These results suggests that hyperhomocysteinemia-induced atherosclerosis and/or thrombosis may be caused by homocysteine-induced stimulation of PAI-1 gene expression and secretion in the vasculatures by a mechanism independent from paracrine-autocrine activity of TGFbeta and TNFalpha.
|
10872824 |
2000 |
|
SERPINE1
|
0.400 |
Biomarker
|
disease |
BEFREE |
This overview summarizes the current knowledge on plasminogen activator inhibitor-1 (PAI-1) in the progression of atherosclerosis and the influence of MMPs in aneurysm formation.
|
11795260 |
2001 |
|
SERPINE1
|
0.400 |
Biomarker
|
disease |
BEFREE |
Thus, in addition to the markers of insulin resistance and smoking habit, gene variants of PAI-1 and ACE account for a significant portion of the between-individual variability of circulating PAI-1 antigen concentrations in a general population without clinical evidence of atherosclerosis.
|
9555861 |
1998 |
|
SERPINE1
|
0.400 |
Biomarker
|
disease |
BEFREE |
We and others have hypothesized that the increased PAI-1 may contribute to acceleration of atherosclerosis in this condition and in other states characterized by insulin resistance as well.
|
8281664 |
1994 |
|
SERPINE1
|
0.400 |
Biomarker
|
disease |
BEFREE |
We demonstrated that the increase of sICAM-1, sVCAM-1 and PAI-1, together with decrease of omentin-1 led to a proinflammatory imbalance pointing to the presence of subclinical atherosclerosis, and improving CVD risk stratification in non-smoking patients at early stage MetS beyond traditional scores.
|
31349950 |
2019 |
|
SERPINE1
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We tested the hypothesis that leptin induces PAI-1 and inhibits tPA expression using human coronary artery endothelial cells (HCAEC) in culture as these cells play an important role in atherosclerosis.
|
20051227 |
2010 |